The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma

• Status: Completed
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to verify the role of adding cisplatin chemotherapy to the intensity-modulated radiotherapy (IMRT) for stage II nasopharyngeal carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• pathological confirmed squamous cell carcinoma, WHO II-III type,

• clinical stage II (UICC 7th edition, 2009)

• Karnovsky performance score > 70

• first course of radiotherapy, without radiotherapy and chemotherapy history for other head and neck cancer.

• anticipated life span more than 6 month

• Hemoglobin > 120g/L, WBC > 4.0x10*9/L, Plt > 100x10*9/L

• liver and renal function under the 1.25 normal upper limit

• with written consent information

Exclusion Criteria:

• have other cancer history

• have chemotherapy history

• have radiotherapy history

• have head and neck surgery history(exclusion lymph node biopsy)

• evidence showed distant metastasis or other cancer

• other severe medical comorbidity